Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

Date
2013
Author
RASMUSSEN, S.
GARBER, A. J.
BHARGAVA, A.
DHARMALINGAM, M.
SKJOTH, T. V.
Satman, I.
PHILIS-TSIMIKAS, A.
DEL PRATO, S.
Metadata
Show full item record
Abstract
Aim: The efficacy and safety of insulin degludec (IDeg), a new basal insulin with an ultra-long duration of action, was compared to sitagliptin (Sita) in a 26-week, open-label trial.
URI
http://hdl.handle.net/20.500.12627/144726
https://doi.org/10.1111/dom.12115
Collections